Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

This study has been completed.
Information provided by (Responsible Party):
QRxPharma Inc. Identifier:
First received: January 22, 2010
Last updated: May 15, 2012
Last verified: May 2012
This is a Phase 3, two-arm, double-blind study of efficacy and safety of Q8003 in patients who have undergone primary unilateral total knee arthroplasty

Condition Intervention Phase
Postoperative Pain
Drug: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Study of the Analgesic Efficacy and Safety of Flexible Dose Q8003 Versus Low Dose Q8003 in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty

Resource links provided by NLM:

Further study details as provided by QRxPharma Inc.:

Primary Outcome Measures:
  • Difference in pain intensity scores from baseline [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • Safety: adverse events, opioid-related signs and symptoms [ Time Frame: Throughout the 48-hour period and during the voluntary safety extension period. ]

Enrollment: 141
Study Start Date: February 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Q8003, Flexible dose
Drug: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)
IR Capsules, flexible dose, every 4 to 6 hours
Experimental: 2
Q8003, Low dose
Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.

Detailed Description:

This Phase 3 study is a two-arm, double-blind study to:

  • compare the analgesic efficacy and safety of the flexible regimen of Q8003 (6 mg/4 mg up to 24 mg/16 mg) administered every 4-6 hours over a 48-hour Treatment Period versus low dose Q8003 (every 4-6 hours 3 mg/2 mg with a 6 mg/4 mg loading dose) to inpatients with moderate to severe postoperative pain who have undergone primary unilateral total knee arthroplasty.
  • to evaluate the efficacy and safety of Q8003 when administered in the Voluntary Extension Period starting at 48 hours after the initial dosing and extending up to Day 12.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age at time of enrollment.
  • If female, be at least one year post-menopausal, surgically sterile or practicing effective contraceptive, be non-lactating, and if of child-bearing potential, have a negative urine pregnancy test result.
  • Have a body mass index (BMI) of 38 kg/m2 or less.
  • Have undergone a primary unilateral total knee arthroplasty performed under under standardized general, spinal or epidural anesthesia.
  • Have developed moderate to severe pain (a score of 2 or more on the 4 point Likert scale and at least 4 on the 11 point NPRS scale within 6 hours of discontinuing PCA on the morning after surgery).

Exclusion Criteria:

  • In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
  • Used opiates continuously (including tramadol) for more than ten days in the past year.
  • Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
  • Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
  • Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
  • Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
  • Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
  • History of abusing licit or illicit drug substances within five (5) years of study entry.
  • Has taken drugs known to interact with morphine or oxycodone metabolism, including, but not limited to, phenothiazines, monoamine oxidase inhibitors (MAOI), amphetamines, and muscle relaxants within the 4 weeks prior to the date of surgery.
  • History of sleep apnea.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01055015

United States, Alabama
Investigator Site
Birmingham, Alabama, United States, 35209
Investigator Site
Sheffield, Alabama, United States, 35660
United States, Arizona
Investigator Site
Phoenix, Arizona, United States, 85023
United States, California
Investigator Site
Laguna Hills, California, United States, 92653
Investigator Site
Long Beach, California, United States, 90806
Investigator Site
Pasadena, California, United States, 91105
United States, Colorado
Investigator Site
Englewood, Colorado, United States, 80110
United States, Florida
Investigator Site
Edgewater, Florida, United States, 32132
Investigator Site
Miami, Florida, United States, 33136
Investigator Site
Sarasota, Florida, United States, 34232
United States, Texas
Investigator Site
Houston, Texas, United States, 77024
Sponsors and Collaborators
QRxPharma Inc.
  More Information

Responsible Party: QRxPharma Inc. Identifier: NCT01055015     History of Changes
Other Study ID Numbers: Q8003-009
Study First Received: January 22, 2010
Last Updated: May 15, 2012

Keywords provided by QRxPharma Inc.:
total knee arthroplasty

Additional relevant MeSH terms:
Pain, Postoperative
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on April 28, 2017